If you believe in the future of the global movement towards electric-powered vehicles, Nio (NYSE:NIO) is a company that should be on your radar. As an investor, you'll find that Nio stock is easily affordable and the company has strong growth potential.Source: Sundry Photography / Shutterstock.com Don't get me wrong: there is always risk involved if you're investing in a start-up company. That being said, it's undeniable that the electric-vehicle market is disrupting the automotive industry as we know it. And as a business enterprise, Nio is still in the first innings of the game.It is true that the novel-coronavirus crisis took a serious toll on the global automotive market. But that actually provided an opportunity to accumulate shares of Nio stock while panic was setting in. Today, the data suggests that the fears were overstated. The electric-vehicle market is here to stay, and so is Nio.InvestorPlace – Stock Market News, Stock Advice & Trading Tips Nio Stock at a GlanceA look back at the historical price action shows that Nio stock has been above $10 not just onec, but twice. The shares first broke above that level in 2018. Then, the buyers pushed Nio shares above $10 again in 2019. * 7 Great Biotech Stocks to Buy and Hold Now The stock could easily have breached that level again in the first half of 2020, but the novel coronavirus crash delayed any prospects of a sustained breakout. What the buyers needed to see was a sign of hope that the electric-vehicle market would recover.Thankfully, there was data to provide encouragement to struggling Nio stockholders, which we'll talk about in just a moment. And now the trend is clearly to the upside, with a real possibility of Nio shares attaining all-time high prices before the year is over. Marking an Inflection PointWhile the global pandemic dented the electric-vehicle market, and the automotive market generally, this shouldn't dissuade anyone considering an investment today. We can't expect the transition from gasoline- and diesel-powered cars to electric vehicles to be perfectly smooth.Despite the bumps in the road, the outlook for the electric-vehicle industry looks bright. Bernstein analyst Mark Newman estimates that the production of electric vehicles will achieve a range between 1.3 million and 1.5 million, depending on this year's market conditions.Moreover, research conducted by Cairn Energy Research Advisors suggests that electric-vehicle sales will surge in 2021. This pickup in sales will likely be driven, at least in part, by various nations' initiatives encouraging people to buy battery-powered automobiles.According to Cairn's estimates, the global sales of electric vehicles next year will increase by 36%. Not only that, but for the very first time, electric-vehicle sales in 2021 will exceed 3 million vehicles.Sam Jaffe, the managing director of Cairn Energy Research Advisors, even seemed to suggest that next year will be a watershed year for the electric-vehicle market: "There's pent-up demand for electric vehicles … We will see a combination of factors make 2021 an inflection point for the sale of electric vehicles." An Outstanding Month for NioAll of the foregoing should benefit Nio's business, of course. But there's also company-specific data that should boost the spirits of any current or prospective Nio shareholder.In the month of May, Nio delivered 3,436 vehicles. That represents astounding year-over-year growth of 215.5%. It's also a record for Nio in terms of monthly vehicle deliveries.In addition, Nio projects an "all-time high in quarterly deliveries" for the second quarter. The company expects up to 158% quarter-on-quarter growth, which would translate to roughly 10,000 cars.In other words, as far as Nio's vehicle sales are concerned, the speed bumps are in the rearview mirror now. The Final Word on Nio StockThe coronavirus slowed down the electric-vehicle industry, but couldn't stop it permanently. Nio is part of this fast-emerging industry, and Nio stockholders can hold their shares in anticipation of a steadily improving market.Louis Navellier had an unconventional start, as a grad student who accidentally built a market-beating stock system — with returns rivaling even Warren Buffett. In his latest feat, Louis discovered the "Master Key" to profiting from the biggest tech revolution of this (or any) generation. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * Top Stock Picker Reveals His Next 1,000% Winner * The 1 Stock All Retirees Must Own * Look What America's Richest Family Is Investing in Now The post Nio's Resurgence Highlights the Emerging Global Electric-Vehicle Market appeared first on InvestorPlace.
from Yahoo Finance https://ift.tt/30FqH3T
Investors who take an interest in Cerecor Inc. (NASDAQ:CERC) should definitely note that the CEO, President…
AstraZeneca (AZN) has agreed to supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine, AZD1222, to Europe’s Inclusive Vaccines Alliance (IVA), with deliveries starting by the end of 2020.Total manufacturing capacity for AZD1222 now stands at two billion doses, says AZN.Spearheaded by Germany, France, Italy and the Netherlands, the IVA says it aims to accelerate the supply of the vaccine and to make it available to other European countries that wish to participate in the initiative.At the same time, UK-based AstraZeneca continues to build several global supply chains, including for Europe. “The company is seeking to expand manufacturing capacity further and is open to collaborating with other companies in order to meet its commitment to support access to the vaccine at no profit during the pandemic” AZN states.Pascal Soriot, CEO of AstraZeneca, commented: “With our European supply chain due to begin production soon, we hope to make the vaccine available widely and rapidly.”Indeed, the company recently entered similar agreements with the UK, US, the Coalition for Epidemic Preparedness Innovations and Gavi the Vaccine Alliance for 700 million doses. It has also agreed a license with the Serum Institute of India for the supply of an additional one billion doses for low and middle-income countries.Oxford University last month announced the start of a Phase II/III UK trial of AZD1222 in about 10,000 adult volunteers. Other late-stage trials are due to begin in a number of countries. AstraZeneca recognizes that the vaccine may not work but is nonetheless progressing the clinical program with speed and scaling up manufacturing at risk.AZD1222 uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus that causes infections in chimpanzees and contains the genetic material of SARS-CoV-2 spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack COVID-19 if it later infects the body.Shares in AstraZeneca are up 3% year-to-date, and analysts are, on average, predicting that 20% further upside potential lies ahead. This comes with a Strong Buy consensus based on 4 recent buy ratings. (See AstraZeneca stock analysis on TipRanks).Related News: Oxford Biomedica Clinches Manufacturing Deal For AstraZeneca’s Covid-19 Vaccine 5 Promising Covid-19 Vaccines Picked For Trump’s Operation Warp Speed What Would a Merger Mean for Gilead? Top Analyst Weighs In More recent articles from Smarter Analyst: * Medtronic Succeeds In Critical US Trial For New Insulin Pump * American Express Scores China Go-Ahead In Milestone Moment * Sorrento Edges Higher On Debt Repayment As Top Analyst Says Buy * Activist Investor Jana Partners Builds 5.9% Stake in Perspecta; Stock Jumps 9% In Pre-Market